A5015231732- Systemic Lupus Erythematosus Research
- Atherosclerosis and Cardiovascular Diseases
- Immune responses and vaccinations
- Immune cells in cancer
- Inflammatory Bowel Disease
- Cytokine Signaling Pathways and Interactions
- IL-33, ST2, and ILC Pathways
- Liver Disease Diagnosis and Treatment
- Renal Diseases and Glomerulopathies
- Cardiac, Anesthesia and Surgical Outcomes
- Gastroesophageal reflux and treatments
- Cardiovascular Health and Risk Factors
- Bariatric Surgery and Outcomes
- Peripheral Neuropathies and Disorders
- Pharmacological Effects of Natural Compounds
- Monoclonal and Polyclonal Antibodies Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Infective Endocarditis Diagnosis and Management
- Chronic Kidney Disease and Diabetes
- Phagocytosis and Immune Regulation
- Medical and Biological Ozone Research
- Stoma care and complications
- Ocular Infections and Treatments
- Diphtheria, Corynebacterium, and Tetanus
- Liver Disease and Transplantation
MedStar Georgetown University Hospital
2022-2025
Georgetown University
2022-2025
Academy of Athens
2021-2024
National and Kapodistrian University of Athens
2021-2024
Georgetown University Medical Center
2023-2024
Biomedical Research Foundation of the Academy of Athens
2021-2023
FORTH Institute of Computer Science
2023
Democritus University of Thrace
2023
Stavros
2023
Saarland University
2023
Amyloid A (AA) amyloidosis is an organ- or life-threatening complication of chronic inflammatory disorders. Here, we review the epidemiology, causes, pathogenesis, clinical features, and diagnostic therapeutic strategies AA amyloidosis.
Objectives In SLE, deregulation of haematopoiesis is characterised by inflammatory priming and myeloid skewing haematopoietic stem progenitor cells (HSPCs). We sought to investigate the role extramedullary (EMH) as a key player for tissue injury in systemic autoimmune disorders. Methods Transcriptomic analysis bone marrow (BM)-derived HSPCs from patients with SLE NZBW/F1 lupus-prone mice was performed combination DNA methylation profile. Trained immunity (TI) induced through β-glucan...
Treatment of Systemic Lupus Erythematosus (SLE) is characterized by a largely empirical approach and relative paucity novel compound development. We sought to stratify SLE patients based on their molecular phenotype identify putative therapeutic compounds for each fingerprint.By the use whole blood RNA-seq data from 120 patients, in data-driven, clinically unbiased manner, we established modules commonly regulated genes (molecular endotypes) re-stratified through hierarchical clustering....
Patients with lupus nephritis (LN) are in urgent need for early diagnosis and therapeutic interventions targeting aberrant molecular pathways enriched affected kidneys.We used mRNA-sequencing effector (spleen) target (kidneys, brain) tissues from control mice at sequential time points, the blood 367 individuals (261 systemic erythematosus (SLE) patients 106 healthy individuals). Comparative cross-tissue cross-species analyses were performed. The human dataset was split into training...
Introduction: The discovery of biologic agents 2 decades ago has transformed ulcerative colitis (UC) therapeutics, as biologics are now considered the mainstay treatment. Despite these treatment advances, a significant number patients develop relapses and experience refractory disease or major side effects while on biologics. recent approval upadacitinib, an oral small molecule selective JAK1 inhibitor, expanded our therapeutic armamentarium, but there is paucity reports describing...
Background: It is estimated that the prevalence of ulcerative colitis (UC) in United States 465 per 100,000 people, with its incidence projected to increase further upcoming years. Although advent biologics has revolutionized UC therapeutics, a substantial proportion patients suffer from refractory disease. Ozanimod an oral sphingosine-1-phosphate receptor modulator been recently approved by US Food and Drug Administration for moderate severe therapy. Real-world experience ozanimod remains...
<h3>Background</h3> Systemic Lupus Erythematosus (SLE) is a prototypic, systemic autoimmune disease that can affect many organs. Current treatment of SLE largely empirical, while the existing immunosuppressive treatments fail to induce remission in over 40% patients. <h3>Methods</h3> Whole blood transcriptome samples were obtained from 95 patients with moderate severe at baseline, 1 month and 6 months after initiation cytotoxic agents (cyclophosphamide, mycophenolate mofetil),...
Introduction: The incidence of various infections in the setting cirrhosis remains to be defined, and it is unclear whether liver dysfunction predisposes specific infections. Reports literature suggest that might a significant risk factor for bacterial endocarditis. In this light, we present case young patient with acute endocarditis complicated by endophthalmitis AIH-induced cirrhosis. Case Description/Methods: A 31-year-old female history autoimmune hepatitis (AIH) presented one day...
<title>Abstract</title> In order to meet the increased demand for effector cells in periphery, systemic inflammation promotes medullary and extramedullary myelopoiesis. Extramedullary hematopoiesis (EMH) is emerging as a key player tissue injury autoimmune disorders. Systemic Lupus Erythematosus (SLE), deregulation of characterized by myeloid skewing trained immunity with priming proinflammatory ‘immune trained’-hematopoietic stem progenitor (HSPCs). Here, use NZBW/F1 lupus-prone model we...
Introduction: Systemic inflammatory diseases, such as psoriasis, lupus, and rheumatoid arthritis, have exhibited a strong association with an increased incidence of cardiovascular events over patient’s lifetime. However, there is limited information regarding outcomes, particularly cardiac arrest, in STEMI patients concurrent IBD. Thus, our study aims to assess potential including IBD, utilizing nationally representative sample adult individuals the United States, specific focus on MACE...
<h3>Purpose</h3> We have previously shown dysregulation of hematopoiesis in the bone marrow (BM) SLE, with skewing towards myeloid lineage and evidence for extramedullary (EMH). EMH results generation effector cells periphery to meet increased demands has been linked peripheral tissue injury by proving an inflammatory license BM-derived cells. sought further explore their contribution disease pathology. <h3>Materials Methods</h3> Meta-analysis blood (PB-) CD34+ transcriptomic data HSPCs from...
Introduction: Infections are a major cause of morbidity and mortality in end-stage liver disease (ESLD). Cirrhosis-associated immune dysfunction (CAID) refers to the system dysregulation observed ESLD. Innate adaptive immunity is clinically evident by increased susceptibility bacterial, fungal, viral infections. We present case young patient with multiple concomitant opportunistic infections attributed secondary Case Description/Methods: A 36-year-old male prior medical history asthma...
Background: Systemic Lupus Erythematosus (SLE) is characterized by lack of treatment diversity, largely empirical decisions, and paucity novel compound development. Objectives: We sought to stratify SLE patients based on their molecular phenotype predict personalized therapeutic compounds, tailored the fingerprint each subgroup. Methods: performed a co-expression analysis using our publicly available whole blood RNA-seq data 120 patients. Modules commonly regulated genes were established...
Background: Extramedullary hematopoiesis (EMH) is increasingly recognized as an integral component of systemic inflammatory diseases; compared to their bone marrow counterparts, hematopoietic progenitors EMH have enhanced role in target organ damage 1,2 . We found that β-glucan -a non-specific inducer reprograming innate immunity- results dramatic with marked increase Long-Term (LT)-HSCs, massive splenomegaly and worsening nephritis the NZB/W F1 lupus murine model (unpublished data)....
Despite improvements in understanding the pathogenic mechanisms of primary glomerular diseases, therapy still remains nonspecific. We sought to identify novel therapies targeting kidney-intrinsic injury distinct glomerulonephritides through computational systems biology approaches. defined unique transcriptional landscape within kidneys from patients with focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), immunoglobulin A nephropathy (IgAN), membranous (MN) and thin...